Autosomal dominant polycystic kidney disease (ADPKD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Indication name: Autosomal dominant polycystic kidney disease (ADPKD)

Autosomal dominant polycystic kidney disease (ADPKD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the formation of cysts within the kidneys, caused by genetic changes in the PKD1, PKD2, GANAB and DNAJB11 genes. Thelansis Epidemiology study indicates approximately one per 800-1000 population carries a mutation for this condition. Approximately 85-90% of patients with ADPKD have ADPKD1; most of the remaining patients have ADPKD2.

Competitive landscape of ADPKD includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of ADPKD across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

ADPKD Market Forecasting: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing , Market Event and Product Event , Country specific Forecast Model, Market uptake and patient share uptake , Attribute Analysis , Analog Analysis , Disease burden and pricing scenario, Summary and Insights.

 

Read more: Autosomal dominant polycystic kidney disease (ADPKD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

S. No        Asset        Company        Partner        Phase

1        Bardoxolone Methyl        Reata        Phase III

2        Venglustat malate        Sanofi        Phase III

3        Iixivaptan        Palladio        Phase II

4        Oxypurinol        XORTX Pharma        Phase II

5        Tesevatinib        Kadmon/Symphony Evolution        Phase II

6        RGLS-4326        Regulus Therapeutics        Phase I

7        Ricolinostat        Celgene/Regency Pharma        Phase I

8        CFTR Signalsome Activators        Discovery Biomed        Pre-clinical

9        PKD-003        Goldfinch Bio        Pre-clinical

10        PKD-004        Goldfinch Bio        Pre-clinical

11        PKD-005        Goldfinch Bio        Pre-clinical

12        Polycystic Kidney Disease Ttherapy        Eloxx Pharma        Pre-clinical

13        Apatone        IC-MedTech        Pre-clinical